Aplastic Anemia

Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in the development of novel therapeutics. He strongly believes in the concept of being a physician-scientist. He completed a year of clinical research fellowship in Neuro-Oncology at Cleveland Clinic, where he investigated the role of EGFR mutations and ALK rearrangement in

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials. Furthermore, she leads the Chronic Graft-versus-Host Disease/Long-Term Follow-Up Program for patients who have received hematopoietic cell transplantation or other immune

Firas El Chaer, MD, is an assistant professor of medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms. Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at

Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center. He is